Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity.

The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.

Study Overview

• Status: Completed
• Conditions: Skin Cancer
• Intervention / Treatment: Other: Data extraction from medical files

• Study Type: Observational
• Enrollment (Actual): 373

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1020
    • CHU Brugmann

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Identification of all patients who have undergone surgical excision of benign or malignant facial and/or eyelid tumors over the past 5 years in the Dermatology and/or Ophthalmology Departments of the CHU Saint-Pierre and CHU Brugmann hospitals.

Description

Inclusion Criteria:

Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

Exclusion Criteria:

Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Age	Age of the patient at the time of diagnose	5 minutes
Sex	Sex of the patient	5 minutes
Name of the department in which the patient is followed	Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital	5 minutes
Tumor anatomical location	Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.	5 minutes
Tumor size	Tumor size in millimeters	5 minutes
Laterality	Laterality: left, right, median	5 minutes
Multiple or single tumor	Multiple or single tumor	5 minutes
Primitive tumor or recidive	Primitive tumor or recidive	5 minutes
Risk factor: phototype	Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.	5 minutes
Risk factor: immunosuppression (yes/no)	Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma	5 minutes
Risk factor: keratosis	Actinic keratosis of the face	5 minutes
Risk factor: solar exposition (yes/no)	Lived in a sunny European country> 1 year, lived in a sunny country outside Europe> 1 year, sunbed use> 1 session, history of solar erythema during childhood.	5 minutes
Diagnosis	Time between the appearance of the tumor and the first consultation	5 minutes
Locoregional extension report (yes/no)	Locoregional extension report (yes/no)	5 minutes
Histological diagnosis of the tumor	Histological diagnosis of the tumor	5 minutes
Healthy or invaded margins	Healthy or invaded margins	5 minutes
Superficial or infiltrating tumor	Superficial or infiltrating tumor	5 minutes
Diagnostic method	Diagnostic method: curettage, punch, biopsy, flattening	5 minutes
Surgical management method	Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen	5 minutes

Collaborators and Investigators

• Sponsor: Brugmann University Hospital
• Investigators: Principal Investigator: Nosria Boulakhrif, CHU Brugmann

Study record dates

Study Major Dates

• Study Start (Actual): February 9, 2021
• Primary Completion (Actual): July 28, 2021
• Study Completion (Actual): July 28, 2021

Study Registration Dates

• First Submitted: May 6, 2021
• First Submitted That Met QC Criteria: May 10, 2021
• First Posted (Actual): May 14, 2021

Study Record Updates

• Last Update Posted (Actual): March 8, 2022
• Last Update Submitted That Met QC Criteria: March 7, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Eye Diseases; Head and Neck Neoplasms; Eye Neoplasms; Eyelid Diseases; Facial Neoplasms; Skin Neoplasms; Eyelid Neoplasms
• Other Study ID Numbers: CHUB-BOULAKHRIF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No